Olaratumab: First Global Approval

@article{Shirley2016OlaratumabFG,
  title={Olaratumab: First Global Approval},
  author={Matt Shirley},
  journal={Drugs},
  year={2016},
  volume={77},
  pages={107-112}
}
Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab acts by selectively binding PDGFRα, thereby blocking PDGF ligand binding and inhibiting PDGFRα activation and downstream signalling. In October 2016, olaratumab received its first… 
Pharmacokinetics and systems pharmacology of monoclonal antibody olaratumab for inoperable soft tissue sarcoma
TLDR
Olaratumab is an antagonist of platelet-derived growth factor receptor alpha (PDGFR alpha) that prevents the binding of PDGF ligands to this receptor, consequently inhibiting subsequent dimerization of the receptor and downstream signal transduction, thereby inhibiting carcinogenesis.
Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
TLDR
A double-blind, placebo-controlled, randomized Phase III study is being performed in order to confirm the survival advantage of olaratumab and to provide definitive drug confirmation by regulators.
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
TLDR
The potential role of PDGFRα signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olatoratumab are discussed.
Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas
TLDR
RT significantly delayed time to tumor quintupling compared to no RT, but no difference in tumor growth was seen between mice receiving isotype or 1E10Fc treatment regardless of concurrent RT, and 1E 10Fc did not act as a radiosensitizer in this primary STS model.
Olaratumab’s failure in soft tissue sarcoma
TLDR
A retrospective analysis of adult patients with advanced-/metastatic soft tissue sarcomas treated with at least two cycles of Olaratumab at a tertiary care center in Lebanon during the period from January 1, 2017 to December 31, 2018 shows results similar to those reported in the literature.
Olaratumab for the treatment of soft-tissue sarcoma.
TLDR
Some of the preclinical and early clinical data of olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olarumab in Sarcomas are described.
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
TLDR
Current and future developments relating to enhanced effector function, such as the ability to form multimers on the target cell surface, are discussed, chiefly involving the combination of anti-CD20 mAbs with various other agents to resensitize patients to treatment.
Bispecific anti-mPDGFRβ x cotinine scFv-Cκ-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRβ expressing cells.
TLDR
It is observed that a bispecific anti-murine platelet-derived growth factor receptor beta (mPDGFRβ) x cotinine single-chain variable fragment ( scFv)-kappa constant region (Cκ)-scFv fusion protein and cotinin-duocarmycin can form an ADC-like complex to induce cytotoxicity against mPDG FRβ expressing cells.
Molecular imaging of platelet-derived growth factor receptor-alpha (PDGFRα) in papillary thyroid cancer using immuno-PET.
TLDR
The presented work has the potential to allow physicians to identify papillary thyroid cancer patients at risk of metastases by using the novel immuno-PET imaging assay based on PDGFRα-targeting antibody [64Cu]Cu-NOTA-D13C6, which represents a novel and promising radiotracer.
...
1
2
3
4
...

References

SHOWING 1-10 OF 20 REFERENCES
Abstract CT145: A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS)
TLDR
The PK of Olara alone and with Dox was consistent with previously reported data and Olara+Dox had an acceptable safety profile, which is consistent with those previously reported.
A randomized phase 2 study of a human antiplatelet-derived growth factor α (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
TLDR
This open-label phase 2 study assessed the safety and efficacy of olaratumab added to paclitaxel/carboplatin (P/C) versus P/C alone in previously untreated patients with advanced NSCLC with progression-free survival estimated by the Kaplan-Meier method.
Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α
TLDR
The results of preclinical studies and the frequent expression of PDGFRα in many types of cancer and in cancer‐associated stroma support a rationale for the clinical development of IMC‐3G3, a fully human monoclonal antibody of the immunoglobulin G subclass 1 that binds to the human PDGF receptor α with high affinity and blocks PDGF ligand binding and PDG FRα activation.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
TLDR
An open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA, finding progression-free survival in phase 2 was 6.6 months and the efficacy was assessed.
Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.
TLDR
The expression of ligands for the PDGFR in ovarian tumors, cell lines and peritoneal fluid was assayed using RT-PCR, immunohistochemistry (IHC) and ELISA, suggesting that receptor targeting has a role in ovarian cancer treatment.
Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer
TLDR
Early developing livers were used to identify genes that might play a primary role in HCC and PDGFRα inhibition in hepatoma cells led to diminution of tumor cell survival and proliferation and thus might be of therapeutic significance.
Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
TLDR
There is compelling evidence that targeting PDGFRα with IMC-3G3 delays the progression of early metastatic foci and reduces the size of more established lesions, and prolongs survival in animal models.
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
TLDR
The observed median PFS and overall survival in this large, international study can serve as a benchmark for future studies of doxorubicin in metastatic soft tissue sarcoma.
Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target
TLDR
The data suggest that 3G3 may be useful for the treatment of tumors that express PDGFRα, a type III receptor tyrosine kinase that is expressed on a variety of tumor types.
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
TLDR
This phase 3 randomised controlled trial assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorbicin alone.
...
1
2
...